InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-51.8%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Melnick David A., Directeur Médical. Director active across 1 company, notably Spero Therapeutics, Inc.. Aggregated, 4 disclosures have been recorded. History available since 26 August 2021. The latest transaction was filed on 1 February 2022 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations4 total
38,014 shares0Common StockSEC:0000899243-22-004594:0
38,014 shares0Common StockSEC:0000899243-22-004594
24,067 shares0Common StockSEC:0000899243-21-034503:0
24,067 shares0Common StockSEC:0000899243-21-034503
4 of 4 declarations
About Melnick David A.
David A. Melnick serves as Chief Medical Officer at Spero Therapeutics, Inc. In this role, he is responsible for leading the company's medical initiatives and clinical research. With a strong background in the pharmaceutical sector, David contributes to innovation and treatment improvement. His leadership is essential in ensuring that Spero Therapeutics adheres to ethical and scientific standards.
